
    
      This study will initially randomize participants to one of 2 arms in a 1:1 ratio to receive
      either a 5.6 mg/kg fixed dose regimen or an up-titration dose regimen of patritumab
      deruxtecan (HER3-DXd, U3-1402).
    
  